{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:21Z","timestamp":1786982781668,"version":"build-2736575974"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100010109","name":"Medical University of Graz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40265-026-02323-z","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T09:24:15Z","timestamp":1777886655000},"page":"909-925","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Large Vessel Vasculitis: Recent Advances in Pathophysiology and Targeted Therapies"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3578-8205","authenticated-orcid":false,"given":"Myriam","family":"Reisch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7582-1514","authenticated-orcid":false,"given":"Jens","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6783-6422","authenticated-orcid":false,"given":"Philipp","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"2323_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1\u201311. https:\/\/doi.org\/10.1002\/art.37715.","journal-title":"Arthritis Rheum"},{"key":"2323_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13075-021-02450-w","volume":"23","author":"KJ Li","year":"2021","unstructured":"Li KJ, Semenov D, Turk M, Pope J. A meta-analysis of the epidemiology of giant cell arteritis across time and space. Arthritis Res Ther. 2021;23:82. https:\/\/doi.org\/10.1186\/s13075-021-02450-w.","journal-title":"Arthritis Res Ther"},{"key":"2323_CR3","doi-asserted-by":"publisher","first-page":"4982","DOI":"10.1093\/rheumatology\/keab406","volume":"60","author":"M Rutter","year":"2021","unstructured":"Rutter M, Bowley J, Lanyon PC, Grainge MJ, Pearce FA. A systematic review and meta-analysis of the incidence rate of Takayasu arteritis. Rheumatology (Oxford). 2021;60:4982\u201390. https:\/\/doi.org\/10.1093\/rheumatology\/keab406.","journal-title":"Rheumatology (Oxford)"},{"key":"2323_CR4","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1002\/art.42325","volume":"74","author":"C Ponte","year":"2022","unstructured":"Ponte C, Grayson PC, Robson JC, Suppiah R, Gribbons KB, Judge A, et al. 2022 American College of Rheumatology\/EULAR Classification Criteria for Giant Cell Arteritis. Arthritis Rheumatol. 2022;74:1881\u20139. https:\/\/doi.org\/10.1002\/art.42325.","journal-title":"Arthritis Rheumatol"},{"key":"2323_CR5","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1136\/ard-2022-223482","volume":"81","author":"PC Grayson","year":"2022","unstructured":"Grayson PC, Ponte C, Suppiah R, Robson JC, Gribbons KB, Judge A, et al. 2022 American College of Rheumatology\/EULAR classification criteria for Takayasu arteritis. Ann Rheum Dis. 2022;81:1654\u201360. https:\/\/doi.org\/10.1136\/ard-2022-223482.","journal-title":"Ann Rheum Dis"},{"key":"2323_CR6","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ijcard.2017.02.086","volume":"235","author":"SJ Park","year":"2017","unstructured":"Park SJ, Kim HJ, Park H, Hann HJ, Kim KH, Han S, et al. Incidence, prevalence, mortality and causes of death in Takayasu Arteritis in Korea\u2014a nationwide, population-based study. Int J Cardiol. 2017;235:100\u20134. https:\/\/doi.org\/10.1016\/j.ijcard.2017.02.086.","journal-title":"Int J Cardiol"},{"key":"2323_CR7","first-page":"468","volume":"115","author":"A Winkler","year":"2018","unstructured":"Winkler A, True D. Giant cell arteritis: 2018 review. Mo Med. 2018;115:468\u201370.","journal-title":"Mo Med"},{"key":"2323_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000039723","volume":"103","author":"L Teng","year":"2024","unstructured":"Teng L, Li L, Cui D, An R, Jin J. Polymyalgia rheumatica and giant cell arteritis: a bidirectional Mendelian randomization study. Medicine (Baltimore). 2024;103:e39723. https:\/\/doi.org\/10.1097\/MD.0000000000039723.","journal-title":"Medicine (Baltimore)"},{"key":"2323_CR9","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/rheumatology\/kew273","volume":"56","author":"C Dejaco","year":"2017","unstructured":"Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology (Oxford). 2017;56:506\u201315. https:\/\/doi.org\/10.1093\/rheumatology\/kew273.","journal-title":"Rheumatology (Oxford)"},{"key":"2323_CR10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4103\/0974-2069.107235","volume":"6","author":"P Vaideeswar","year":"2013","unstructured":"Vaideeswar P, Deshpande JR. Pathology of Takayasu arteritis: a brief review. Ann Pediatr Cardiol. 2013;6:52\u20138. https:\/\/doi.org\/10.4103\/0974-2069.107235.","journal-title":"Ann Pediatr Cardiol"},{"key":"2323_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2022.105494","volume":"90","author":"L Moreel","year":"2023","unstructured":"Moreel L, Betrains A, Molenberghs G, Vanderschueren S, Blockmans D. Epidemiology and predictors of relapse in giant cell arteritis: a systematic review and meta-analysis. Joint Bone Spine. 2023;90:105494. https:\/\/doi.org\/10.1016\/j.jbspin.2022.105494.","journal-title":"Joint Bone Spine"},{"key":"2323_CR12","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1161\/CIRCULATIONAHA.116.027094","volume":"136","author":"C Comarmond","year":"2017","unstructured":"Comarmond C, Biard L, Lambert M, Mekinian A, Ferfar Y, Kahn JE, et al. Long-term outcomes and prognostic factors of complications in Takayasu Arteritis: a multicenter study of 318 patients. Circulation. 2017;136:1114\u201322. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.027094.","journal-title":"Circulation"},{"key":"2323_CR13","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/art.41774","volume":"73","author":"M Maz","year":"2021","unstructured":"Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol. 2021;73:1349\u201365. https:\/\/doi.org\/10.1002\/art.41774.","journal-title":"Arthritis Rheumatol"},{"key":"2323_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00083","volume":"10","author":"JC Graver","year":"2019","unstructured":"Graver JC, Boots AMH, Haacke EA, Diepstra A, Brouwer E, Sandovici M. Massive B-cell infiltration and organization into artery tertiary lymphoid organs in the aorta of large vessel giant cell arteritis. Front Immunol. 2019;10:83. https:\/\/doi.org\/10.3389\/fimmu.2019.00083.","journal-title":"Front Immunol"},{"key":"2323_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-020-00948-x","volume":"22","author":"R Watanabe","year":"2020","unstructured":"Watanabe R, Berry GJ, Liang DH, Goronzy JJ, Weyand CM. Pathogenesis of giant cell arteritis and takayasu arteritis-similarities and differences. Curr Rheumatol Rep. 2020;22:68. https:\/\/doi.org\/10.1007\/s11926-020-00948-x.","journal-title":"Curr Rheumatol Rep"},{"key":"2323_CR16","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1161\/CIRCULATIONAHA.109.872903","volume":"121","author":"J Deng","year":"2010","unstructured":"Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation. 2010;121:906\u201315. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.872903.","journal-title":"Circulation"},{"key":"2323_CR17","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1080\/14397595.2019.1570999","volume":"29","author":"A Kurata","year":"2019","unstructured":"Kurata A, Saito A, Hashimoto H, Fujita K, Ohno SI, Kamma H, et al. Difference in immunohistochemical characteristics between Takayasu arteritis and giant cell arteritis: it may be better to distinguish them in the same age. Mod Rheumatol. 2019;29:992\u20131001. https:\/\/doi.org\/10.1080\/14397595.2019.1570999.","journal-title":"Mod Rheumatol"},{"key":"2323_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cells13030267","author":"M Paroli","year":"2024","unstructured":"Paroli M, Caccavale R, Accapezzato D. Giant Cell Arteritis: advances in understanding pathogenesis and implications for clinical practice. Cells. 2024. https:\/\/doi.org\/10.3390\/cells13030267.","journal-title":"Cells"},{"issue":"6","key":"2323_CR19","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/acr.20043","volume":"62","author":"A Garc\u00eda-Mart\u00ednez","year":"2010","unstructured":"Garc\u00eda-Mart\u00ednez A, Hern\u00e1ndez-Rodr\u00edguez J, Esp\u00edgol-Frigol\u00e9 G, Prieto-Gonz\u00e1lez S, Butjosa M, Segarra M, et al. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor \u03b1 and interleukin\u20106) in the long\u2010term followup of patients with giant cell arteritis. Arthritis Care Res (Hoboken). 2010;62(6):835\u201341. https:\/\/doi.org\/10.1002\/acr.20043.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2323_CR20","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/rheumatology\/keu526","volume":"54","author":"KS van der Geest","year":"2015","unstructured":"van der Geest KS, Abdulahad WH, Rutgers A, Horst G, Bijzet J, Arends S, et al. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. Rheumatology (Oxford). 2015;54:1397\u2013402. https:\/\/doi.org\/10.1093\/rheumatology\/keu526.","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 103","key":"2323_CR21","first-page":"102","volume":"35","author":"L Pulsatelli","year":"2017","unstructured":"Pulsatelli L, Boiardi L, Assirelli E, Pazzola G, Muratore F, Addimanda O, et al. Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study. Clin Exp Rheumatol. 2017;35(Suppl 103):102\u201310.","journal-title":"Clin Exp Rheumatol"},{"key":"2323_CR22","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1007\/s10067-020-05066-8","volume":"39","author":"Y Sun","year":"2020","unstructured":"Sun Y, Kong X, Cui X, Dai X, Ma L, Chen H, et al. The value of interleukin-6 in predicting disease relapse for Takayasu arteritis during 2-year follow-up. Clin Rheumatol. 2020;39:3417\u201325. https:\/\/doi.org\/10.1007\/s10067-020-05066-8.","journal-title":"Clin Rheumatol"},{"key":"2323_CR23","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1093\/mr\/roac099","volume":"33","author":"M Harigai","year":"2023","unstructured":"Harigai M, Miyamae T, Hashimoto H, Yoshida A, Yamashita K, Nakaoka Y. A multicentre, large-scale, observational study of tocilizumab in patients with Takayasu arteritis in Japan: the ACTEMRA(R) (ACT)-Bridge study. Mod Rheumatol. 2023;33:998\u20131006. https:\/\/doi.org\/10.1093\/mr\/roac099.","journal-title":"Mod Rheumatol"},{"key":"2323_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152640","volume":"71","author":"A Martin-Gutierrez","year":"2025","unstructured":"Martin-Gutierrez A, Loricera J, Aldasoro V, Maiz O, de Miguel E, Galindez-Agirregoikoa E, et al. Relapses in Giant Cell Arteritis treated with Tocilizumab. Retrospective multicenter study of 407 patients in clinical practice. Semin Arthritis Rheum. 2025;71:152640. https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152640.","journal-title":"Semin Arthritis Rheum"},{"key":"2323_CR25","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.ard.2025.01.049","volume":"84","author":"R Zorc","year":"2025","unstructured":"Zorc R, Redmond C, Sylvester M, Maclean M, Yamamoto de Almeida L, Quinn KA, et al. A coding single nucleotide polymorphism in the interleukin-6 receptor enhances IL-6 signalling in CD4 T cells and predicts treatment response to Tocilizumab in Giant Cell Arteritis. Ann Rheum Dis. 2025;84:1401\u201311. https:\/\/doi.org\/10.1016\/j.ard.2025.01.049.","journal-title":"Ann Rheum Dis"},{"key":"2323_CR26","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/pro.3519","volume":"27","author":"R Morris","year":"2018","unstructured":"Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK\/STAT pathway. Protein Sci. 2018;27:1984\u20132009. https:\/\/doi.org\/10.1002\/pro.3519.","journal-title":"Protein Sci"},{"key":"2323_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abe4627","volume":"14","author":"M Shemesh","year":"2021","unstructured":"Shemesh M, Lochte S, Piehler J, Schreiber G. IFNAR1 and IFNAR2 play distinct roles in initiating type I interferon-induced JAK-STAT signaling and activating STATs. Sci Signal. 2021;14:eabe4627. https:\/\/doi.org\/10.1126\/scisignal.abe4627.","journal-title":"Sci Signal"},{"key":"2323_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102796","volume":"127","author":"M Vieira","year":"2022","unstructured":"Vieira M, Regnier P, Maciejewski-Duval A, Le Joncour A, Darasse-Jeze G, Rosenzwajg M, et al. Interferon signature in giant cell arteritis aortitis. J Autoimmun. 2022;127:102796. https:\/\/doi.org\/10.1016\/j.jaut.2022.102796.","journal-title":"J Autoimmun"},{"key":"2323_CR29","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/annrheumdis-2019-216900","volume":"79","author":"P Regnier","year":"2020","unstructured":"Regnier P, Le Joncour A, Maciejewski-Duval A, Desbois AC, Comarmond C, Rosenzwajg M, et al. Targeting JAK\/STAT pathway in Takayasu\u2019s arteritis. Ann Rheum Dis. 2020;79:951\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216900.","journal-title":"Ann Rheum Dis"},{"key":"2323_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/cei\/uxae046","volume":"217","author":"B Savioli","year":"2024","unstructured":"Savioli B, Torquato HFV, Paredes-Gamero EJ, Franco A, Gigek CO, Artigiani Neto R, et al. Effector CD4+ T-cell subsets in Takayasu arteritis-differences between the peripheral blood and the aorta. Clin Exp Immunol. 2024;217:183\u201394. https:\/\/doi.org\/10.1093\/cei\/uxae046.","journal-title":"Clin Exp Immunol"},{"key":"2323_CR31","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.it.2017.01.006","volume":"38","author":"N Amatya","year":"2017","unstructured":"Amatya N, Garg AV, Gaffen SL. IL-17 signaling: The Yin and the Yang. Trends Immunol. 2017;38:310\u201322. https:\/\/doi.org\/10.1016\/j.it.2017.01.006.","journal-title":"Trends Immunol"},{"key":"2323_CR32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","volume":"23","author":"KHG Mills","year":"2023","unstructured":"Mills KHG. IL-17 and IL-17-producing cells in protection versus pathology. Nat Rev Immunol. 2023;23:38\u201354. https:\/\/doi.org\/10.1038\/s41577-022-00746-9.","journal-title":"Nat Rev Immunol"},{"key":"2323_CR33","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1002\/art.34647","volume":"64","author":"M Samson","year":"2012","unstructured":"Samson M, Audia S, Fraszczak J, Trad M, Ornetti P, Lakomy D, et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum. 2012;64:3788\u201398. https:\/\/doi.org\/10.1002\/art.34647.","journal-title":"Arthritis Rheum"},{"key":"2323_CR34","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1093\/rheumatology\/kev102","volume":"54","author":"F Ciccia","year":"2015","unstructured":"Ciccia F, Rizzo A, Guggino G, Cavazza A, Alessandro R, Maugeri R, et al. Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis. Rheumatology (Oxford). 2015;54:1596\u2013604. https:\/\/doi.org\/10.1093\/rheumatology\/kev102.","journal-title":"Rheumatology (Oxford)"},{"key":"2323_CR35","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1136\/annrheumdis-2014-205261","volume":"73","author":"A Marquez","year":"2014","unstructured":"Marquez A, Hernandez-Rodriguez J, Cid MC, Solans R, Castaneda S, Fernandez-Contreras ME, et al. Influence of the IL17A locus in giant cell arteritis susceptibility. Ann Rheum Dis. 2014;73:1742\u20135. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205261.","journal-title":"Ann Rheum Dis"},{"key":"2323_CR36","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/art.39037","volume":"67","author":"D Saadoun","year":"2015","unstructured":"Saadoun D, Garrido M, Comarmond C, Desbois AC, Domont F, Savey L, et al. Th1 and Th17 cytokines drive inflammation in Takayasu arteritis. Arthritis Rheumatol. 2015;67:1353\u201360. https:\/\/doi.org\/10.1002\/art.39037.","journal-title":"Arthritis Rheumatol"},{"key":"2323_CR37","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1016\/S0140-6736(25)01436-9","volume":"406","author":"P Cacoub","year":"2025","unstructured":"Cacoub P, Vieira M, Langford CA, Tazi Mezalek Z, Saadoun D. Large-vessel vasculitis. Lancet. 2025;406:2017\u201332. https:\/\/doi.org\/10.1016\/S0140-6736(25)01436-9.","journal-title":"Lancet"},{"key":"2323_CR38","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/rheumatology\/kei266","volume":"45","author":"MC Park","year":"2006","unstructured":"Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu\u2019s arteritis. Rheumatology (Oxford). 2006;45:545\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/kei266.","journal-title":"Rheumatology (Oxford)"},{"key":"2323_CR39","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.clim.2005.09.010","volume":"118","author":"NK Tripathy","year":"2006","unstructured":"Tripathy NK, Gupta PC, Nityanand S. High TNF-alpha and low IL-2 producing T cells characterize active disease in Takayasu\u2019s arteritis. Clin Immunol. 2006;118:154\u20138. https:\/\/doi.org\/10.1016\/j.clim.2005.09.010.","journal-title":"Clin Immunol"},{"key":"2323_CR40","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1136\/annrheumdis-2021-220873","volume":"81","author":"M Corbera-Bellalta","year":"2022","unstructured":"Corbera-Bellalta M, Alba-Rovira R, Muralidharan S, Espigol-Frigole G, Rios-Garces R, Marco-Hernandez J, et al. Blocking GM-CSF receptor \u03b1 with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis. Ann Rheum Dis. 2022;81:524\u201336. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220873.","journal-title":"Ann Rheum Dis"},{"key":"2323_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1164","volume":"9","author":"WF Jiemy","year":"2020","unstructured":"Jiemy WF, van Sleen Y, van der Geest KS, Ten Berge HA, Abdulahad WH, Sandovici M, et al. Distinct macrophage phenotypes skewed by local granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) are associated with tissue destruction and intimal hyperplasia in giant cell arteritis. Clinical & Translational Immunology. 2020;9:e1164. https:\/\/doi.org\/10.1002\/cti2.1164.","journal-title":"Clinical & Translational Immunology"},{"key":"2323_CR42","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf408","author":"S Xu","year":"2025","unstructured":"Xu S, Jiemy WF, Zhang A, Walinga F, Nijenhuis M, Hensema E, et al. Crosstalk between macrophages and fibroblasts contributes to inflammation and damage in giant cell arteritis. Rheumatology (Oxford). 2025. https:\/\/doi.org\/10.1093\/rheumatology\/keaf408.","journal-title":"Rheumatology (Oxford)"},{"key":"2323_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103589","volume":"23","author":"E Hysa","year":"2024","unstructured":"Hysa E, Casabella A, Gotelli E, Campitiello R, Schenone C, Genova C, et al. Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic literature review highlighting differences from the idiopathic forms. Autoimmun Rev. 2024;23:103589. https:\/\/doi.org\/10.1016\/j.autrev.2024.103589.","journal-title":"Autoimmun Rev"},{"key":"2323_CR44","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1093\/rheumatology\/keaf001","volume":"64","author":"I Monjo-Henry","year":"2025","unstructured":"Monjo-Henry I, Nieto-Carvalhal B, Uyaguari M, Garcia-Carazo S, Balsa A, de Miguel E, et al. Circulating PD-1hi CXCR5- and CXCR5+ CD4 T cells are elevated in patients with newly diagnosed giant cell arteritis, and predict relapse. Rheumatology (Oxford). 2025;64:3996\u20134004. https:\/\/doi.org\/10.1093\/rheumatology\/keaf001.","journal-title":"Rheumatology (Oxford)"},{"key":"2323_CR45","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/art.43110","volume":"77","author":"RT Maughan","year":"2025","unstructured":"Maughan RT, Macdonald-Dunlop E, Haroon-Rashid L, Sorensen L, Chaddock N, Masters S, et al. Proteomic profiling of the large-vessel vasculitis spectrum identifying shared signatures of innate immune activation and stromal remodeling. Arthritis Rheumatol. 2025;77:884\u2013900. https:\/\/doi.org\/10.1002\/art.43110.","journal-title":"Arthritis Rheumatol"},{"key":"2323_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.hbpd.2025.11.005","author":"BQ Huang","year":"2025","unstructured":"Huang BQ, Tian YX, Li LJ. Identification of therapeutic targets for giant cell arteritis through integrated analysis of multi-omics datasets. Hepatobiliary Pancreat Dis Int. 2025. https:\/\/doi.org\/10.1016\/j.hbpd.2025.11.005.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"2323_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-025-03673-x","volume":"27","author":"K Xu","year":"2025","unstructured":"Xu K, Li T, Gao N, Zhang Y, Yang Y, Zhao H, et al. Integrated bulk and single-cell transcriptomics identifies shared and specific immune signatures in Takayasu Arteritis. Arthritis Res Ther. 2025;27:209. https:\/\/doi.org\/10.1186\/s13075-025-03673-x.","journal-title":"Arthritis Res Ther"},{"key":"2323_CR48","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1016\/S2665-9913(24)00064-X","volume":"6","author":"G Borrego-Yaniz","year":"2024","unstructured":"Borrego-Yaniz G, Ortiz-Fernandez L, Madrid-Paredes A, Kerick M, Hernandez-Rodriguez J, Mackie SL, et al. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study. Lancet Rheumatol. 2024;6:e374\u201383. https:\/\/doi.org\/10.1016\/S2665-9913(24)00064-X.","journal-title":"Lancet Rheumatol."},{"key":"2323_CR49","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ajhg.2020.11.014","volume":"108","author":"L Ortiz-Fern\u00e1ndez","year":"2021","unstructured":"Ortiz-Fern\u00e1ndez L, Saruhan-Direskeneli G, Alibaz-Oner F, Kaymaz-Tahra S, Coit P, Kong X, et al. Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. Am J Hum Genet. 2021;108:84\u201399. https:\/\/doi.org\/10.1016\/j.ajhg.2020.11.014.","journal-title":"Am J Hum Genet"},{"key":"2323_CR50","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s10038-023-01198-2","volume":"69","author":"D Danda","year":"2024","unstructured":"Danda D, Goel R, Kabeerdoss J, Sun C, Danda S, Lincy Franklin A, et al. Angiogenesis related genes in Takayasu Arteritis (TAK): robust association with Tag SNPs of IL-18 and FGF-2 in a South Asian Cohort. J Hum Genet. 2024;69:13\u20138. https:\/\/doi.org\/10.1038\/s10038-023-01198-2.","journal-title":"J Hum Genet"},{"key":"2323_CR51","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/art.42738","volume":"76","author":"ML Robinette","year":"2024","unstructured":"Robinette ML, Weeks LD, Kramer RJ, Agrawal M, Gibson CJ, Yu Z, et al. Association of somatic TET2 mutations with Giant Cell Arteritis. Arthritis Rheumatol. 2024;76:438\u201343. https:\/\/doi.org\/10.1002\/art.42738.","journal-title":"Arthritis Rheumatol"},{"key":"2323_CR52","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/ard-2023-224933","volume":"83","author":"F Gutierrez-Rodrigues","year":"2024","unstructured":"Gutierrez-Rodrigues F, Wells KV, Jones AI, Hironaka D, Rankin C, Gadina M, et al. Clonal haematopoiesis across the age spectrum of vasculitis patients with Takayasu\u2019s arteritis, ANCA-associated vasculitis and giant cell arteritis. Ann Rheum Dis. 2024;83:508\u201317. https:\/\/doi.org\/10.1136\/ard-2023-224933.","journal-title":"Ann Rheum Dis"},{"key":"2323_CR53","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79:19\u201330. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215672.","journal-title":"Ann Rheum Dis"},{"key":"2323_CR54","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017;377:317\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1613849.","journal-title":"N Engl J Med"},{"key":"2323_CR55","doi-asserted-by":"publisher","first-page":"e736","DOI":"10.1016\/S2665-9913(23)00265-5","volume":"5","author":"S Unizony","year":"2023","unstructured":"Unizony S, Matza MA, Jarvie A, O\u2019Dea D, Fernandes AD, Stone JH. Treatment for Giant Cell Arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study. Lancet Rheumatol. 2023;5:e736\u201342. https:\/\/doi.org\/10.1016\/S2665-9913(23)00265-5.","journal-title":"Lancet Rheumatol"},{"key":"2323_CR56","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1093\/rheumatology\/keae400","volume":"64","author":"F Muratore","year":"2025","unstructured":"Muratore F, Marvisi C, Cassone G, Ricordi C, Boiardi L, Mancuso P, et al. Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: results from the extension of the TOPAZIO study. Rheumatology (Oxford). 2025;64:3057\u201362. https:\/\/doi.org\/10.1093\/rheumatology\/keae400.","journal-title":"Rheumatology (Oxford)"},{"key":"2323_CR57","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/rheumatology\/kead215","volume":"63","author":"F Muratore","year":"2024","unstructured":"Muratore F, Marvisi C, Cassone G, Boiardi L, Mancuso P, Besutti G, et al. Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: the role of imaging in a prospective observational study. Rheumatology (Oxford). 2024;63:64\u201371.","journal-title":"Rheumatology (Oxford)"},{"key":"2323_CR58","doi-asserted-by":"publisher","first-page":"e619","DOI":"10.1016\/S2665-9913(21)00152-1","volume":"3","author":"L Christ","year":"2021","unstructured":"Christ L, Seitz L, Scholz G, Sarbu AC, Amsler J, Butikofer L, et al. Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study. Lancet Rheumatol. 2021;3:e619\u201326. https:\/\/doi.org\/10.1016\/S2665-9913(21)00152-1.","journal-title":"Lancet Rheumatol"},{"key":"2323_CR59","doi-asserted-by":"publisher","first-page":"5616","DOI":"10.1093\/rheumatology\/keaf317","volume":"64","author":"L Christ","year":"2025","unstructured":"Christ L, Seitz L, Scholz G, B\u00fctikofer L, Kollert F, Reichenbach S, et al. Efficacy of tocilizumab monotherapy after ultrashort glucocorticoid administration to treat giant cell arteritis: three-year follow-up. Rheumatology (Oxford). 2025;64:5616\u201321. https:\/\/doi.org\/10.1093\/rheumatology\/keaf317.","journal-title":"Rheumatology (Oxford)"},{"key":"2323_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152508","volume":"68","author":"MK Nielsen","year":"2024","unstructured":"Nielsen MK, Nielsen AW, Donskov AO, Hansen IT, Nielsen BD, Mork C, et al. Taper versus discontinuation of tocilizumab in patients with giant cell arteritis: real-world experience from a tertiary center. Semin Arthritis Rheum. 2024;68:152508. https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152508.","journal-title":"Semin Arthritis Rheum"},{"key":"2323_CR61","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMoa2413449","volume":"392","author":"D Blockmans","year":"2025","unstructured":"Blockmans D, Penn SK, Setty AR, Schmidt WA, Rubbert-Roth A, Hauge EM, et al. A Phase 3 trial of Upadacitinib for giant-cell arteritis. N Engl J Med. 2025;392:2013\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2413449.","journal-title":"N Engl J Med"},{"key":"2323_CR62","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1136\/annrheumdis-2021-221961","volume":"81","author":"MJ Koster","year":"2022","unstructured":"Koster MJ, Crowson CS, Giblon RE, Jaquith JM, Duarte-Garcia A, Matteson EL, et al. Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study. Ann Rheum Dis. 2022;81:861\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221961.","journal-title":"Ann Rheum Dis"},{"key":"2323_CR63","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1016\/S2665-9913(23)00101-7","volume":"5","author":"N Venhoff","year":"2023","unstructured":"Venhoff N, Schmidt WA, Bergner R, Rech J, Unger L, Tony HP, et al. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Rheumatol. 2023;5:e341\u201350. https:\/\/doi.org\/10.1016\/S2665-9913(23)00101-7.","journal-title":"Lancet Rheumatol"},{"key":"2323_CR64","doi-asserted-by":"crossref","unstructured":"Novartis. Novartis provides update on Phase III GCAptAIN study of Cosentyx\u00ae in giant cell arteritis (GCA). 2025. https:\/\/www.novartis.com\/news\/media-releases\/novartis-provides-update-phase-iii-gcaptain-study-cosentyx-giant-cell-arteritis-gca. Accessed 8 Apr 2026","DOI":"10.69645\/DQFX6833"},{"key":"2323_CR65","doi-asserted-by":"publisher","first-page":"5118","DOI":"10.1093\/rheumatology\/keaf250","volume":"64","author":"A Tomelleri","year":"2025","unstructured":"Tomelleri A, Bond M, Marvisi C, Campochiaro C, Farina N, Venerandi B, et al. Secukinumab is effective and safe for patients with giant cell arteritis after tocilizumab failure. Rheumatology (Oxford). 2025;64:5118\u201322. https:\/\/doi.org\/10.1093\/rheumatology\/keaf250.","journal-title":"Rheumatology (Oxford)"},{"key":"2323_CR66","unstructured":"Novartis. Novartis Cosentyx\u00ae meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR). 2025. https:\/\/www.novartis.com\/news\/media-releases\/novartis-cosentyx-meets-primary-and-all-secondary-endpoints-phase-iii-trial-patients-polymyalgia-rheumatica-pmr. Accessed 8 Apr 2026"},{"key":"2323_CR67","doi-asserted-by":"publisher","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","volume":"146","author":"GS Hoffman","year":"2007","unstructured":"Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146:621\u201330. https:\/\/doi.org\/10.7326\/0003-4819-146-9-200705010-00004.","journal-title":"Ann Intern Med"},{"key":"2323_CR68","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1136\/ard.2007.082115","volume":"67","author":"VM Martinez-Taboada","year":"2008","unstructured":"Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L, Lopez-Longo J, Figueroa M, Belzunegui J, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis. 2008;67:625\u201330. https:\/\/doi.org\/10.1136\/ard.2007.082115.","journal-title":"Ann Rheum Dis"},{"key":"2323_CR69","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1136\/annrheumdis-2013-203586","volume":"73","author":"R Seror","year":"2014","unstructured":"Seror R, Baron G, Hachulla E, Debandt M, Larroche C, Puechal X, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis. 2014;73:2074\u201381. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203586.","journal-title":"Ann Rheum Dis"},{"key":"2323_CR70","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1136\/annrheumdis-2021-221865","volume":"81","author":"MC Cid","year":"2022","unstructured":"Cid MC, Unizony SH, Blockmans D, Brouwer E, Dagna L, Dasgupta B, et al. Efficacy and safety of Mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81:653\u201361. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221865.","journal-title":"Ann Rheum Dis"},{"key":"2323_CR71","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/art.40044","volume":"69","author":"CA Langford","year":"2017","unstructured":"Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, et al. A randomized, double-blind trial of Abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 2017;69:837\u201345. https:\/\/doi.org\/10.1002\/art.40044.","journal-title":"Arthritis Rheumatol"},{"key":"2323_CR72","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.semarthrit.2018.04.004","volume":"48","author":"R Conway","year":"2018","unstructured":"Conway R, O\u2019Neill L, Gallagher P, McCarthy GM, Murphy CC, Veale DJ, et al. Ustekinumab for refractory giant cell arteritis: a prospective 52-week trial. Semin Arthritis Rheum. 2018;48:523\u20138. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.04.004.","journal-title":"Semin Arthritis Rheum"},{"key":"2323_CR73","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/acr.24200","volume":"73","author":"MA Matza","year":"2021","unstructured":"Matza MA, Fernandes AD, Stone JH, Unizony SH. Ustekinumab for the treatment of giant cell arteritis. Arthritis Care Res (Hoboken). 2021;73:893\u20137. https:\/\/doi.org\/10.1002\/acr.24200.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2323_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2026.01.009","author":"JP Makhzoum","year":"2026","unstructured":"Makhzoum JP, Cid MC, Samson M, Henes J, Sch\u00f6nau V, Espigol-Frigole G, et al. A phase 2, randomised, placebo-controlled study of guselkumab in adults with new-onset or relapsing giant cell arteritis. Ann Rheum Dis. 2026. https:\/\/doi.org\/10.1016\/j.ard.2026.01.009.","journal-title":"Ann Rheum Dis"},{"key":"2323_CR75","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/art.10262","volume":"46","author":"GS Hoffman","year":"2002","unstructured":"Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46:1309\u201318. https:\/\/doi.org\/10.1002\/art.10262.","journal-title":"Arthritis Rheum"},{"key":"2323_CR76","first-page":"495","volume":"19","author":"RF Spiera","year":"2001","unstructured":"Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001;19:495\u2013501.","journal-title":"Clin Exp Rheumatol"},{"key":"2323_CR77","doi-asserted-by":"publisher","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","volume":"134","author":"JA Jover","year":"2001","unstructured":"Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134:106\u201314. https:\/\/doi.org\/10.7326\/0003-4819-134-2-200101160-00010.","journal-title":"Ann Intern Med"},{"key":"2323_CR78","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1002\/art.22754","volume":"56","author":"AD Mahr","year":"2007","unstructured":"Mahr AD, Jover JA, Spiera RF, Hernandez-Garcia C, Fernandez-Gutierrez B, Lavalley MP, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56:2789\u201397. https:\/\/doi.org\/10.1002\/art.22754.","journal-title":"Arthritis Rheum"},{"key":"2323_CR79","unstructured":"Samson M BA, Outh R, Grobost V, Lifermann F, DIREZ G, Ribeiro E, Oziol E, Devauchelle V, Ebbo M, Limal N, Paule R, Bienvenu B, Poulet A, Miranda S, Benhamou Y, Quemeneur T, Dingremont C, Ramon A, Simorre B, Reynaud Q, AGARD C, Espitia O, Mekinian A, Alexandra J, Berthoux E, Perard L, Baudet A, Mesbah R, Lac\u00f4te-Delarbre D, Stievenart J, Andr\u00e9 M, Allain J, Jaussaud R, Magnant J, Servettaz A, De Boysson H, Ruivard M, Terrier B, REGENT A, Cransac A, Fournel I, Devilliers H, Bonnotte B. MEthotrexate versus TOcilizumab for treatment of Giant cell Arteritis (METOGiA trial): a multicenter, randomized, controlled trial. [abstract]. Arthritis Rheumatol. 2026;77 (suppl 9). https:\/\/acrabstracts.org\/abstract\/methotrexate-versus-tocilizumab-for-treatment-of-giant-cell-arteritis-metogia-trial-a-multicenter-randomized-controlled-trial\/"},{"key":"2323_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1069013","volume":"9","author":"J Kramari\u010d","year":"2022","unstructured":"Kramari\u010d J, Rotar \u017d, Tom\u0161i\u010d M, Ho\u010devar A. Performance of leflunomide as a steroid-sparing agent in giant cell arteritis: a single-center, open-label study. Front Med. 2022;9:1069013. https:\/\/doi.org\/10.3389\/fmed.2022.1069013.","journal-title":"Front Med"},{"key":"2323_CR81","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/1756-185X.14319","volume":"25","author":"S Das","year":"2022","unstructured":"Das S, Goswami RP, Sinha D, Ghosal A, Datta A, Sarkar S. Efficacy of leflunomide as a steroid-sparing agent in treatment of Indian giant cell arteritis patients: a 2-year follow-up study. Int J Rheum Dis. 2022;25:650\u20138. https:\/\/doi.org\/10.1111\/1756-185X.14319.","journal-title":"Int J Rheum Dis"},{"key":"2323_CR82","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10067-018-4232-x","volume":"38","author":"A Hocevar","year":"2019","unstructured":"Hocevar A, Jese R, Rotar Z, Tomsic M. Does leflunomide have a role in giant cell arteritis? An open-label study. Clin Rheumatol. 2019;38:291\u20136. https:\/\/doi.org\/10.1007\/s10067-018-4232-x.","journal-title":"Clin Rheumatol"},{"key":"2323_CR83","first-page":"S44","volume":"34","author":"J Loricera","year":"2016","unstructured":"Loricera J, Blanco R, Hernandez JL, Castaneda S, Humbria A, Ortego N, et al. Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review. Clin Exp Rheumatol. 2016;34:S44-53.","journal-title":"Clin Exp Rheumatol"},{"key":"2323_CR84","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaut.2018.04.002","volume":"91","author":"A Mekinian","year":"2018","unstructured":"Mekinian A, Resche-Rigon M, Comarmond C, Soriano A, Constans J, Alric L, et al. Efficacy of tocilizumab in Takayasu arteritis: multicenter retrospective study of 46 patients. J Autoimmun. 2018;91:55\u201360. https:\/\/doi.org\/10.1016\/j.jaut.2018.04.002.","journal-title":"J Autoimmun"},{"key":"2323_CR85","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jjcc.2020.12.011","volume":"77","author":"M Isobe","year":"2021","unstructured":"Isobe M, Maejima Y, Saji M, Tateishi U. Evaluation of tocilizumab for intractable Takayasu arteritis and (18)F-fluorodeoxyglucose-positron emission tomography for detecting inflammation under tocilizumab treatment. J Cardiol. 2021;77:539\u201344. https:\/\/doi.org\/10.1016\/j.jjcc.2020.12.011.","journal-title":"J Cardiol"},{"key":"2323_CR86","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211020917","volume":"13","author":"D Prieto-Pena","year":"2021","unstructured":"Prieto-Pena D, Bernabeu P, Vela P, Narvaez J, Fernandez-Lopez JC, Freire-Gonzalez M, et al. Tocilizumab in refractory Caucasian Takayasu\u2019s arteritis: a multicenter study of 54 patients and literature review. Ther Adv Musculoskelet Dis. 2021;13:1759720X211020917. https:\/\/doi.org\/10.1177\/1759720X211020917.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2323_CR87","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1136\/annrheumdis-2017-211878","volume":"77","author":"Y Nakaoka","year":"2018","unstructured":"Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis. 2018;77:348\u201354. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211878.","journal-title":"Ann Rheum Dis"},{"key":"2323_CR88","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1093\/rheumatology\/kez630","volume":"59","author":"Y Nakaoka","year":"2020","unstructured":"Nakaoka Y, Isobe M, Tanaka Y, Ishii T, Ooka S, Niiro H, et al. Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. Rheumatology (Oxford). 2020;59:2427\u201334. https:\/\/doi.org\/10.1093\/rheumatology\/kez630.","journal-title":"Rheumatology (Oxford)"},{"key":"2323_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02311-y","volume":"22","author":"A Mekinian","year":"2020","unstructured":"Mekinian A, Saadoun D, Vicaut E, Thietart S, Lioger B, Jego P, et al. Tocilizumab in treatment-naive patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial. Arthritis Res Ther. 2020;22:218. https:\/\/doi.org\/10.1186\/s13075-020-02311-y.","journal-title":"Arthritis Res Ther"},{"key":"2323_CR90","doi-asserted-by":"publisher","DOI":"10.1177\/20406223221131715","volume":"13","author":"H Liao","year":"2022","unstructured":"Liao H, Du J, Li T, Pan L. Tocilizumab for faster and safer remission of Takayasu\u2019s arteritis. Ther Adv Chronic Dis. 2022;13:20406223221131715. https:\/\/doi.org\/10.1177\/20406223221131715.","journal-title":"Ther Adv Chronic Dis"},{"key":"2323_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152018","volume":"55","author":"J Wang","year":"2022","unstructured":"Wang J, Dai X, Ma L, Wu S, Jin X, Ji Z, et al. Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: a prospective study. Semin Arthritis Rheum. 2022;55:152018. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152018.","journal-title":"Semin Arthritis Rheum"},{"key":"2323_CR92","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1136\/annrheumdis-2021-220832","volume":"81","author":"X Kong","year":"2022","unstructured":"Kong X, Sun Y, Dai X, Wang L, Ji Z, Chen H, et al. Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study. Ann Rheum Dis. 2022;81:117\u201323. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220832.","journal-title":"Ann Rheum Dis"},{"key":"2323_CR93","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003985","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Fang C, Wang L, Li J, Yang Y, Zhang L, et al. Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre. RMD Open. 2024. https:\/\/doi.org\/10.1136\/rmdopen-2023-003985.","journal-title":"RMD Open"},{"key":"2323_CR94","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/art.42496","volume":"75","author":"X Tian","year":"2023","unstructured":"Tian X, Li M, Jiang N, Zhao Y, Li J, Zhou Y, et al. Comparative efficacy of Secukinumab versus Tumor Necrosis Factor Inhibitors for the treatment of Takayasu arteritis. Arthritis Rheumatol. 2023;75:1415\u201323. https:\/\/doi.org\/10.1002\/art.42496.","journal-title":"Arthritis Rheumatol"},{"key":"2323_CR95","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1002\/art.20300","volume":"50","author":"GS Hoffman","year":"2004","unstructured":"Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum. 2004;50:2296\u2013304. https:\/\/doi.org\/10.1002\/art.20300.","journal-title":"Arthritis Rheum"},{"key":"2323_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102634","volume":"19","author":"P Mertz","year":"2020","unstructured":"Mertz P, Kleinmann JF, Lambert M, Puechal X, Bonnin A, Boulon C, et al. Infliximab is an effective glucocorticoid-sparing treatment for Takayasu arteritis: results of a multicenter open-label prospective study. Autoimmun Rev. 2020;19:102634. https:\/\/doi.org\/10.1016\/j.autrev.2020.102634.","journal-title":"Autoimmun Rev"},{"key":"2323_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.723506","volume":"8","author":"C Campochiaro","year":"2021","unstructured":"Campochiaro C, Tomelleri A, Sartorelli S, Sembenini C, Papa M, Fallanca F, et al. A prospective observational study on the efficacy and safety of Infliximab-biosimilar (CT-P13) in patients with Takayasu arteritis (TAKASIM). Front Med Lausanne. 2021;8:723506. https:\/\/doi.org\/10.3389\/fmed.2021.723506.","journal-title":"Front Med Lausanne"},{"key":"2323_CR98","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1136\/ard.2008.093260","volume":"67","author":"ES Molloy","year":"2008","unstructured":"Molloy ES, Langford CA, Clark TM, Gota CE, Hoffman GS. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis. 2008;67:1567\u20139. https:\/\/doi.org\/10.1136\/ard.2008.093260.","journal-title":"Ann Rheum Dis"},{"key":"2323_CR99","first-page":"922","volume":"30","author":"L Quartuccio","year":"2012","unstructured":"Quartuccio L, Schiavon F, Zuliani F, Carraro V, Catarsi E, Tavoni AG, et al. Long-term efficacy and improvement of health-related quality of life in patients with Takayasu\u2019s arteritis treated with infliximab. Clin Exp Rheumatol. 2012;30:922\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"2323_CR100","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1002\/acr.21636","volume":"64","author":"J Schmidt","year":"2012","unstructured":"Schmidt J, Kermani TA, Bacani AK, Crowson CS, Matteson EL, Warrington KJ. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup. Arthritis Care Res (Hoboken). 2012;64:1079\u201383. https:\/\/doi.org\/10.1002\/acr.21636.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2323_CR101","doi-asserted-by":"publisher","first-page":"6192","DOI":"10.1093\/rheumatology\/keaf341","volume":"64","author":"A Mekinian","year":"2025","unstructured":"Mekinian A, Meneses S, Biard L, Dagna L, Novikov P, Salvarani C, et al. Effectiveness of intravenous infliximab versus subcutaneous adalimumab in Takayasu arteritis: multicenter retrospective study. Rheumatology (Oxford). 2025;64:6192\u2013200. https:\/\/doi.org\/10.1093\/rheumatology\/keaf341.","journal-title":"Rheumatology (Oxford)"},{"key":"2323_CR102","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1093\/rheumatology\/kead387","volume":"63","author":"J Wang","year":"2024","unstructured":"Wang J, Kong X, Ma L, Ding Z, Chen H, Chen R, et al. Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis: an open-label study. Rheumatology (Oxford). 2024;63:1359\u201367. https:\/\/doi.org\/10.1093\/rheumatology\/kead387.","journal-title":"Rheumatology (Oxford)"},{"key":"2323_CR103","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1093\/rheumatology\/keae013","volume":"63","author":"DP Misra","year":"2024","unstructured":"Misra DP. Comment on: treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis. Rheumatology (Oxford). 2024;63:e156\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/keae013.","journal-title":"Rheumatology (Oxford)"},{"key":"2323_CR104","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1093\/rheumatology\/keab635","volume":"61","author":"A Mekinian","year":"2022","unstructured":"Mekinian A, Biard L, Dagna L, Novikov P, Salvarani C, Espitia O, et al. Efficacy and safety of TNF-\u03b1 antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. Rheumatology (Oxford). 2022;61:1376\u201384. https:\/\/doi.org\/10.1093\/rheumatology\/keab635.","journal-title":"Rheumatology (Oxford)"},{"key":"2323_CR105","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.semarthrit.2021.09.010","volume":"51","author":"F Alibaz-Oner","year":"2021","unstructured":"Alibaz-Oner F, Kaymaz-Tahra S, Bayindir O, Yazici A, Ince B, Kalkan K, et al. Biologic treatments in Takayasu\u2019s arteritis: a comparative study of tumor necrosis factor inhibitors and tocilizumab. Semin Arthritis Rheum. 2021;51:1224\u20139. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.09.010.","journal-title":"Semin Arthritis Rheum"},{"key":"2323_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103275","volume":"22","author":"DP Misra","year":"2023","unstructured":"Misra DP, Singh K, Rathore U, Patro P, Tomelleri A, Campochiaro C, et al. The effectiveness of tocilizumab and its comparison with tumor necrosis factor alpha inhibitors for Takayasu arteritis: a systematic review and meta-analysis. Autoimmun Rev. 2023;22:103275. https:\/\/doi.org\/10.1016\/j.autrev.2023.103275.","journal-title":"Autoimmun Rev"},{"key":"2323_CR107","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/art.40037","volume":"69","author":"CA Langford","year":"2017","unstructured":"Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, et al. A randomized, double-blind trial of Abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis. Arthritis Rheumatol. 2017;69:846\u201353. https:\/\/doi.org\/10.1002\/art.40037.","journal-title":"Arthritis Rheumatol"},{"key":"2323_CR108","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/art.1780370420","volume":"37","author":"GS Hoffman","year":"1994","unstructured":"Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum. 1994;37:578\u201382. https:\/\/doi.org\/10.1002\/art.1780370420.","journal-title":"Arthritis Rheum"},{"key":"2323_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152446","volume":"66","author":"S Kaymaz-Tahra","year":"2024","unstructured":"Kaymaz-Tahra S, Bayindir O, Ince B, Ozdemir \u0130sik O, Kutu ME, Karakas O, et al. Comparison of methotrexate and azathioprine as the first-line steroid-sparing immunosuppressive agents in patients with Takayasu\u2019s arteritis. Semin Arthritis Rheum. 2024;66:152446. https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152446.","journal-title":"Semin Arthritis Rheum"},{"key":"2323_CR110","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3109\/03009742.2011.633553","volume":"41","author":"AW de Souza","year":"2012","unstructured":"de Souza AW, da Silva MD, Machado LS, Oliveira AC, Pinheiro FA, Sato EI. Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study. Scand J Rheumatol. 2012;41:227\u201330. https:\/\/doi.org\/10.3109\/03009742.2011.633553.","journal-title":"Scand J Rheumatol"},{"key":"2323_CR111","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.semarthrit.2019.06.009","volume":"50","author":"X Cui","year":"2020","unstructured":"Cui X, Dai X, Ma L, Yang C, Tan W, Zhang L, et al. Efficacy and safety of leflunomide treatment in Takayasu arteritis: case series from the East China cohort. Semin Arthritis Rheum. 2020;50:59\u201365. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.06.009.","journal-title":"Semin Arthritis Rheum"},{"key":"2323_CR112","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003992","author":"F Peron Filho","year":"2024","unstructured":"Peron Filho F, Moreira AS, Janes ALF, de Souza AWS. Effectiveness and safety of adalimumab compared with leflunomide in patients with Takayasu arteritis: a retrospective cohort study. RMD Open. 2024. https:\/\/doi.org\/10.1136\/rmdopen-2023-003992.","journal-title":"RMD Open"},{"key":"2323_CR113","doi-asserted-by":"publisher","DOI":"10.1177\/2040622320975233","volume":"11","author":"C Wu","year":"2020","unstructured":"Wu C, Sun Y, Cui X, Wu S, Ma L, Chen H, et al. Effectiveness and safety of methotrexate versus leflunomide in 12-month treatment for Takayasu arteritis. Ther Adv Chronic Dis. 2020;11:2040622320975233. https:\/\/doi.org\/10.1177\/2040622320975233.","journal-title":"Ther Adv Chronic Dis"},{"key":"2323_CR114","doi-asserted-by":"publisher","DOI":"10.1177\/2040622320922019","volume":"11","author":"X Dai","year":"2020","unstructured":"Dai X, Cui X, Sun Y, Ma L, Jiang L. Effectiveness and safety of leflunomide compared with cyclophosphamide as induction therapy in Takayasu\u2019s arteritis: an observational study. Ther Adv Chronic Dis. 2020;11:2040622320922019. https:\/\/doi.org\/10.1177\/2040622320922019.","journal-title":"Ther Adv Chronic Dis"},{"key":"2323_CR115","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20930114","volume":"12","author":"S Ying","year":"2020","unstructured":"Ying S, Xiaomeng C, Xiaomin D, Jiang L, Peng L, Lili M, et al. Efficacy and safety of leflunomide versus cyclophosphamide for initial-onset Takayasu arteritis: a prospective cohort study. Ther Adv Musculoskelet Dis. 2020;12:1759720X20930114. https:\/\/doi.org\/10.1177\/1759720X20930114.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2323_CR116","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.carpath.2018.01.004","volume":"33","author":"S Manku","year":"2018","unstructured":"Manku S, Wong W, Luo Z, Seidman MA, Alabdurubalnabi Z, Rey K, et al. IL-6 expression is correlated with increased T-cell proliferation and survival in the arterial wall in giant cell arteritis. Cardiovasc Pathol. 2018;33:55\u201361. https:\/\/doi.org\/10.1016\/j.carpath.2018.01.004.","journal-title":"Cardiovasc Pathol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02323-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02323-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02323-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:40:06Z","timestamp":1778856006000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02323-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":116,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2323"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02323-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MR: Consultancy: Lilly; Adboard\/speaker fees: Alfasigma, Novartis. JT: Consultancy: AbbVie, Janssen, Lilly, Novartis, CSL Behring\/Vifor, GSK, AstraZeneca; Speaker Honoraria: AbbVie, Galapagos, Janssen, BMS, Lilly, Vifor, StreamedUp, CSL Behring\/Vifor, GSK, AstraZeneca; Research funding: BMS, GSK; Patent application: Pending patent application for the use of secukinumab in GCA. PB: Adboard\/speaker fees by Johnsson and Johnsson, AbbVie, Lilly and UCB, Novartis; Project grants: Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"MR performed the literature search and drafted the manuscript. JT and PB reviewed the content critically for intellectual input and revised the manuscript. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}